Key Highlights

  • Net revenues were USD 78.0 million against an estimate of USD 77.58 million and USD 69.0 million a year earlier.
  • EPS was USD -0.05 against an estimate of USD -0.06, while GAAP net loss per share was USD 0.19.
  • The company licensed Profhilo for the United States and expanded Evolysse rights to Europe, Canada, Australia and New Zealand.
  • Cash and cash equivalents were USD 41.7 million at September 30, with USD 10.0 million drawn on a revolving facility.

Evolus (NASDAQ:EOLS) operates in the cash-pay aesthetic market, where customers pay out of pocket. President and CEO David Moatazedi leads a company selling Jeuveau and the Evolysse hyaluronic acid gel collection, and in July it signed a license with IBSA for the injectable Profhilo in the United States. In August it expanded its Symatese agreements to cover Evolysse in Europe, Canada, Australia and New Zealand.

Portfolio Additions and Commercial Priorities

The company said it now holds exclusive rights to commercialize Evolysse in every market where it sells Jeuveau. The Symatese amendments carry upfront payments of EUR 1.4 million, paid in the quarter, and potential additional payments of up to EUR 2.9 million tied to approvals and registrations. Commercialization in the new territories is targeted for 2028, subject to approvals.

The Profhilo agreement requires no upfront or milestone payments, and commercialization in the United States is targeted for 2030, subject to regulatory approval. Evolysse Sculpt and Evolysse Lips are targeted for United States approval in 2026 and 2027, respectively. On October 12, the company also agreed to an option on a procedure-based, sustained-release hair regrowth injectable, with USD 1.5 million of option consideration and a USD 7.5 million upfront payment if exercised.

Third Quarter Results

Net revenues were USD 78.0 million against USD 69.0 million, with product Revenue of USD 77.2 million and service revenue of USD 0.7 million from Jeuveau sales through a Canadian distribution partner. Management attributed the increase to higher Jeuveau and Evolysse sales. EPS was USD -0.05 against an estimate of USD -0.06, and GAAP net loss per share was USD 0.19 against USD 0.24.

Gross profit was USD 50.7 million with a Margin of 65.0%, against 66.5% a year earlier. Selling, general and administrative expenses were USD 52.9 million against USD 52.8 million. Loss from operations was USD 8.4 million against USD 11.5 million, and net loss was USD 12.5 million against USD 15.7 million.

Cash, Debt and Tariffs

Cash and cash equivalents were USD 41.7 million at September 30, against USD 53.8 million at December 31. Net cash used in Operating Activities for nine months was USD 15.5 million against USD 55.1 million. Debt principal outstanding was USD 160.0 million, due in 2029 and 2030, and the USD 30.0 million revolving Facility had USD 10.0 million drawn. Two further Pharmakon term Loan tranches of up to USD 50.0 million each are available at the company's election until December 31, 2026.

In response to Tariff uncertainty on Korean-made products, the company accelerated Jeuveau imports under deferred payment terms, and inventories increased by USD 55.8 million while Accounts Payable increased by USD 62.8 million. Evolysse is subject to a 10% tariff under Section 301, and the company said that, following September guidance, it does not currently view Jeuveau as subject to Section 232 tariffs.

Signposts for the Next Quarter

Net revenues of USD 78.0 million sit alongside a net loss of USD 12.5 million, cash of USD 41.7 million and debt principal of USD 160.0 million.

Management named a set of dated items: United States approvals for Evolysse Sculpt in 2026 and Evolysse Lips in 2027, Evolysse commercialization in the new territories in 2028 and Profhilo in 2030. It also pointed to the December 31, 2026 availability date for the additional Pharmakon tranches and to further tariff refund claims that remain under government review.